189 related articles for article (PubMed ID: 37192586)
41. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Pfeuffer S; Rolfes L; Hackert J; Kleinschnitz K; Ruck T; Wiendl H; Klotz L; Kleinschnitz C; Meuth SG; Pul R
Mult Scler; 2022 Feb; 28(2):257-268. PubMed ID: 33975489
[TBL] [Abstract][Full Text] [Related]
42. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
43. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
44. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
45. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
47. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
[TBL] [Abstract][Full Text] [Related]
48. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
Marastoni D; Foschi M; Eccher C; Crescenzo F; Mazziotti V; Tamanti A; Bajrami A; Camera V; Ziccardi S; Guandalini M; Bosello F; Anni D; Virla F; Turano E; Romoli M; Mariotti R; Pizzini FB; Bonetti B; Calabrese M
Front Immunol; 2024; 15():1343892. PubMed ID: 38404586
[TBL] [Abstract][Full Text] [Related]
49. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O
Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262
[TBL] [Abstract][Full Text] [Related]
50. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
[TBL] [Abstract][Full Text] [Related]
51. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T
Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363
[TBL] [Abstract][Full Text] [Related]
52. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
Tichá V; Počíková Z; Vytlačil J; Štěpánová R
BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
[TBL] [Abstract][Full Text] [Related]
53. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
55. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
56. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study.
Petracca M; Ruggieri S; Barbuti E; Ianniello A; Fantozzi R; Maniscalco GT; Andreone V; Landi D; Marfia GA; Di Gregorio M; Iodice R; Sinisi L; Maida E; Missione R; Coppola C; Bonavita S; Borriello G; Centonze D; Lus G; Pozzilli C; Signoriello E
Neurol Ther; 2022 Sep; 11(3):1193-1208. PubMed ID: 35653061
[TBL] [Abstract][Full Text] [Related]
57. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
[TBL] [Abstract][Full Text] [Related]
58. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
59. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
[TBL] [Abstract][Full Text] [Related]
60. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
